drugset / Trial / NCT00259103
Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor
Phase 2
Completed
72 enrolled
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the safety and efficacy of rhRlx for cervical ripening, when compared to a placebo.
Timeline
- Start
- 2005-11
- Primary completion
- 2006-10
- Completion
- 2006-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Serelaxin | Protein / enzyme biologic | 7.5 ug/kg | Intravenous |
| Subject | Serelaxin | Protein / enzyme biologic | 25 ug/kg | Intravenous |
| Subject | Serelaxin | Protein / enzyme biologic | 75 ug/kg | Intravenous |
Indications
No indication recorded.